Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynucleotides

被引：174

作者：

Krieg A.M. ^{[1
]}

机构：

[1] Coley Pharmaceutical Group, Wellesley, MA 02481

来源：

Current Oncology Reports | 2004年 / 6卷 / 2期

关键词：

Chronic Lymphocytic Leukemia; Plasmacytoid Dendritic Cell; Immune Effect; Vaccine Adjuvant; Peritumoral Injection;

D O I：

10.1007/s11912-004-0019-0

中图分类号：

学科分类号：

摘要：

Tumor immunotherapy has evolved from the use of crude bacterial extracts to chemically synthesized ligands for specific immune receptors, such as Toll-like receptors (TLRs). One of the most promising targets for therapeutic immune activation is TLR9, which detects unmethylated CpG dinucleotides present in viral and prokaryotic genomes, which are generally methylated in host DNA. This review describes the immune effects of synthetic CpG oligonucleotides as TLR9 ligands and their applications in cancer immunotherapy. Copyright © 2004 by Current Science Inc.

引用

页码：88 / 95

页数：7

共 71 条

[21]

Pertl U., Luster A.D., Varki N.M., Et al., IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy, J. Immunol., 166, pp. 6944-6951, (2001)

[22]

Tannenbaum C.S., Tubbs R., Armstrong D., Et al., The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor, J. Immunol., 161, pp. 927-932, (1998)

[23]

Strieter R.M., Polverini P.J., Kunkel S.L., Et al., The functional role of the ELR motif in CXC chemokine-mediated angiogenesis, J. Biol. Chem., 270, pp. 27348-27357, (1995)

[24]

Kemp T.J., Elzey B.D., Griffith T.S., Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation, J. Immunol., 171, pp. 212-218, (2003)

[25]

Ballas Z.K., Krieg A.M., Warren T., Et al., Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs, J. Immunol., 167, pp. 4878-4886, (2001)

[26]

Vollmer J., Weeranta R., Payette P., Et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities, Eur. J. Immunol., 34, pp. 251-262, (2004)

[27]

Marshall J.D., Fearon K., Abbate C., Et al., Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions, J. Leukoc. Biol., 73, pp. 781-792, (2003)

[28]

Hartmann G., Battiany J., Poeck H., Et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells, Eur. J. Immunol., 33, pp. 1633-1641, (2003)

[29]

Davis H.L., Use of CpG DNA for enhancing specific immune responses, Curr. Top. Microbiol. Immunol., 247, pp. 171-183, (2000)

[30]

Hemmi H., Kaisho T., Takeda K., Akira S., The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets, J. Immunol., 170, pp. 3059-3064, (2003)

← 1 2 3 4 5 6 7 8 →